| Literature DB >> 29057546 |
Bing Li1,2, Jinqin Liu2, Yujiao Jia3, Jingya Wang1, Zefeng Xu1,2, Tiejun Qin1, Zhongxun Shi1, Zhen Song4, Shuailing Peng1, Huijun Huang1, Liwei Fang1, Hongli Zhang1, Lijuan Pan1, Naibo Hu1, Shiqiang Qu1, Yue Zhang1,2, Jian Wu5, Na Liu5, Kun Ru3, Gang Huang6, Zhijian Xiao1,2.
Abstract
U2AF1 mutations (U2AF1MT) occur commonly in myelodysplastic syndromes (MDS) without ring sideroblasts. The aim of this study was to investigate the clinical and biological implications of different U2AF1 mutation types in MDS. We performed targeted gene sequencing in a cohort of 511 MDS patients. Eighty-six patients (17%) were found to have U2AF1MT, which occurred more common in younger patients (P = .001) and represented ancestral lesions in a substantial proportion (71%) of cases. ASXL1MT and isolated +8 were significantly enriched in U2AF1MT-positive cases, whereas TP53MT, SF3B1MT, and complex karyotypes were inversely associated with U2AF1MT. U2AFS34 subjects were enriched for isolated +8 and were inversely associated with complex karyotypes. U2AF1MT was significantly associated with anemia, thrombocytopenia, and poor survival in both lower-risk and higher-risk MDS. U2AF1S34 subjects had more frequently platelet levels of <50 × 109 /L (P = .043) and U2AF1Q157 /U2AF1R156 subjects had more frequently hemoglobin concentrations at <80 g/L (P = .008) and more often overt fibrosis (P = .049). In conclusion, our study indicates that U2AF1MT is one of the earliest genetic events in MDS patients and that different types of U2AF1MT have distinct clinical and biological characteristics.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29057546 PMCID: PMC9204509 DOI: 10.1002/gcc.22510
Source DB: PubMed Journal: Genes Chromosomes Cancer ISSN: 1045-2257 Impact factor: 4.263